MTCR
Metacrine, Inc. [MTCR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MTCR Stock Summary
In the News
MTCR Financial details
Company Rating
-
Market Cap
25.48M
Income
-39.32M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
0.58
Dividend %
99.76%
Employees
10
Optionable
No
Shortable
Yes
Earnings
08 Aug 2023
P/E
-0.98
Forward P/E
-
PEG
0.13
P/S
-
P/B
0.67
P/C
-
P/FCF
-1.05
Quick Ratio
11.66
Current Ratio
12.15
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.93
EPS next Y
-
EPS next Q
-
EPS this Y
-62.53%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-18.75%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-46%
ROE
-61%
ROC
-0.46%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.303-0.5905
52W High
-
52W Low
-
RSI
-
Rel Volume
1.6
Avg Volume
52.47K
Volume
83.89K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
-0.74145
-
-
Volatility
0.04%, 0.04%
Prev Close
17.48%
Price
0.5814
Change
-
MTCR Financial Performance
MTCR Frequently Asked Questions
What is Metacrine, Inc. stock symbol ?
Metacrine, Inc. is a US stock , located in San diego of Ca and trading under the symbol MTCR
What is Metacrine, Inc. stock quote today ?
Metacrine, Inc. stock price is $0.5814 today.
Is Metacrine, Inc. stock public?
Yes, Metacrine, Inc. is a publicly traded company.
Company Profile
- Volume Average 52.47K
- Market Capitalization 25.48M
- Employee 10
- CEO Mr. David M. Maggio
- Headquarters San Diego,CA,US
- IPO Date 2020-09-16
-
Website
https://www.metacrine.com 
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
